Thanksgiving 2020: Home, but not Alone: Has your sense of time shifted lately?  Does avoiding people feel bizarre, and has Purell become your new best friend?  Do you spot beauty in surprising places, and feel the rhythm of your breath inside your mask?

On October 21, 2020, Dr. Steven Treon gave a webcast lecture to the Canadian National WMFC Patient Support Group. The main topic was genomic & treatment advances in WM, with the discussion also including the related issues surrounding COVID-19.

Is a cure for Waldenstrom macroglobulinemia on the horizon? In the past several decades Waldenstrom’s survivorship has vastly improved due to safer and more effective treatment drugs. Could this indicate that a cure might be within reach? Patient Power Co-Founder Andrew Schorr speaks with Dr. Steven Treon, director, Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, about his predictions for the future of Waldenstrom macroglobulinemia treatment.

Dr. Steven Treon will be giving a lecture on "New Insights into Waldenstrom's in Session 4 of this virtual Workshop. If you are interested in attending, registration will be closing soon.

The Eastern Massachusetts IWMF Support Group invites WM/Bing-Neel patients and caregivers from across the globe to join us in the first-ever support group meeting focused on this particularly rare WM complication. With Bing-Neel specialists, Dr. Steve Treon and Dr. Jorge Castillo of Dana-Farber Cancer Institute.

Every two years WM experts from around the world meet to discuss the latest research and developments. The last meeting, IWWM-10 was held in New York in October, 2018, and the consensus recommendations on treatment have just been published in The Lancet. Registration (to read the article) is free.

Ibrutinib is a highly active and tolerable therapy for symptomatic, relapsed, or refractory patients with Waldenström macroglobulinemia (WM) and a preferable option for use in previously treated patients, according to a study published in the Journal of Clinical Oncology (2020;JCO2000555. doi:10.1200/JCO.20.00555).

If you’ve ever had questions about clinical trials, this issue will help clarify various aspects of them, from both the doctor’s and the patient’s perspectives. It will be obvious that medical as well as personal reasons need to be considered before making the plunge.

BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) Board of Trustees has reviewed and approved funding an additional $500,000 to renew Dr. Steve Treon's legacy research project.